{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE291nnn/GSE291223/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by array"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291223"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"An analysis of gemcitabine-resistant cholangiocarcinoma cells","description":"Cholangiocarcinoma (CCA) is an aggressive liver bile duct cancer with a poor prognosis. For advanced CCA patients, Gemcitabine (GEM)-based chemotherapy is the standard treatment. Since there is only a 20-30% response rate for advanced CCA patients, it is a critical issue to counteract GEM resistance (GR). We selected two GR iCCA sublines (SSP-25-GR and SNU-1196-GR) from the parental cells (SSP-25 and SNU-1196) to determine the transcriptome profile.","dates":{"publication":"2026/09/16"},"accession":"GSE291223","cross_references":{"GSM":["GSM8831134","GSM8831137","GSM8831135","GSM8831136"],"GPL":["570"],"GSE":["291223"],"taxon":["Homo sapiens"],"PMID":["[42708082]"]}}